Go to Contents
Jennerex Targeting, Attacking, and Eradicating Cancers®

TOP

Jennerex

jennerex

jennerex

SillaJen acquired Jennerex, Inc., an early leader in the oncolytic virotherapy field. Jennerex researchers showed that Pexa-Vec acted in three distinct ways to attack cancer : by infecting and killing cancer cells, by cutting off the blood supply to tumors, and by activating the body’s own immune system to fight cancer.

Scientific Publications 01

Research scientists at Jennerex showed that oncolytic vaccinia viruses were able to be delivered to tumor lesions by intravenous (IV) infusion. The key paper “Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans” showed that the IV delivery of Pexa-Vec (JX-594) resulted in viral infection, viral replication and expression of a transgene marker protein in tumors, in a dose dependent manner, while healthy cells were not infected.

Scientific Publications 02

Research scientists at Jennerex showed that oncolytic vaccinia viruses were able to be delivered to tumor lesions by intravenous (IV) infusion. The key paper “Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans” showed that the IV delivery of Pexa-Vec (JX-594) resulted in viral infection, viral replication and expression of a transgene marker protein in tumors, in a dose dependent manner, while healthy cells were not infected.

Scientific Publications 03

Finally, Jennerex sponsored the Phase 2 trial in Hepatocellular Carcinoma (HCC), which paved a way for SillJen’s Phase 3 PHOCUS trial to be launched. In this dose-finding trial, patients received either a low dose or high dose of Pexa-Vec injected into liver tumors. Patients showed significantly longer overall survival with the high-dose than the low-dose.